The European Medicines Agency confirmed its previous negative opinion and adopted a final negative opinion, recommending that oral cladribine, from Serono Europe Ltd, should not be granted a marketing authorisation. Oral cladribine was intended as disease-modifying therapy in relapsing remitting multiple sclerosis.